{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:51:57Z","timestamp":1792547517392,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T00:00:00Z","timestamp":1638748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T00:00:00Z","timestamp":1638748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100019949","name":"FUJIFILM Toyama Chemical Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100019949","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>In this phase II study, we aimed to investigate the efficacy and safety of single-dose [<jats:sup>131<\/jats:sup>I]meta-iodobenzylguanidine (<jats:sup>131<\/jats:sup>I-mIBG) therapy in patients with refractory pheochromocytoma and paraganglioma (PPGL).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and methods<\/jats:title>\n                <jats:p>This study was designed as an open-label, single-arm, multi-center, phase II clinical trial. The enrolled patients were administered 7.4\u00a0GBq of <jats:sup>131<\/jats:sup>I-mIBG. Its efficacy was evaluated 12 and 24\u00a0weeks later, and its safety was monitored continuously until the end of the study. We evaluated the biochemical response rate as the primary endpoint using the one-sided exact binomial test based on the null hypothesis (\u2264\u20095%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Seventeen patients were enrolled in this study, of which 16 were treated. The biochemical response rate (\u2265\u200950% decrease in urinary catecholamines) was 23.5% (90% confidence interval: 8.5\u201346.1%, <jats:italic>p<\/jats:italic>\u2009=\u20090.009). The radiographic response rates, determined with CT\/MRI according to the response evaluation criteria in solid tumors (RECIST) version 1.1 and <jats:sup>123<\/jats:sup>I-mIBG scintigraphy were 5.9% (0.3%\u201325.0%) and 29.4% (12.4%\u201352.2%), respectively. The most frequent non-hematologic treatment-emergent adverse events (TEAEs) were gastrointestinal symptoms including nausea, appetite loss, and constipation, which were, together, observed in 15 of 16 patients. Hematologic TEAEs up to grade 3 were observed in 14 of 16 patients. No grade 4 or higher TEAEs were observed. All patients had experienced at least one TEAE, but no fatal or irreversible TEAEs were observed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A single dose <jats:sup>131<\/jats:sup>I-mIBG therapy was well tolerated by patients with PPGL, and statistically significantly reduced catecholamine levels compared to the threshold response rate, which may lead to an improved prognosis for these patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12149-021-01699-0","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T09:02:33Z","timestamp":1638781353000},"page":"267-278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["An open-label, single-arm, multi-center, phase II clinical trial of single-dose [131I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1209-7164","authenticated-orcid":false,"given":"Anri","family":"Inaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Shiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Tsushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Jinguji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Kayano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihito","family":"Akatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Yamase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Kunita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomo","family":"Hiromasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyasu","family":"Tomonaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seigo","family":"Kinuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,6]]},"reference":[{"key":"1699_CR1","volume-title":"WHO classification of tumours of endocrine organs","author":"RV Lloyd","year":"2017","unstructured":"Lloyd RV, Osamura RY, Kloppel G, Rosai J. WHO classification of tumours of endocrine organs. 4th ed. Lyon: International Agency of Research on Cancer (IARC); 2017.","edition":"4"},{"issue":"9486","key":"1699_CR2","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(05)67139-5","volume":"366","author":"JW Lenders","year":"2005","unstructured":"Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005;366(9486):665\u201375.","journal-title":"Lancet"},{"issue":"3","key":"1699_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1530\/ERC-13-0494","volume":"21","author":"N Kimura","year":"2014","unstructured":"Kimura N, Takayanagi R, Takizawa N, Itagaki E, Katabami T, Kakoi N, et al. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2014;21(3):405\u201314.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"1699_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3803\/EnM.2020.35.1.157","volume":"35","author":"JH Kim","year":"2020","unstructured":"Kim JH, Moon H, Noh J, Lee J, Kim SG. Epidemiology and prognosis of pheochromocytoma\/paraganglioma in Korea: a nationwide study based on the national health insurance service. Endocrinol Metab (Seoul). 2020;35(1):157\u201364.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"5","key":"1699_CR5","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1161\/01.HYP.29.5.1133","volume":"29","author":"PF Plouin","year":"1997","unstructured":"Plouin PF, Chatellier G, Fofol I, Corvol P. Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension. 1997;29(5):1133\u20139.","journal-title":"Hypertension"},{"key":"1699_CR6","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines\u00ae for Neuroendocrine and Adrenal Tumors Version 2.2020. 2020."},{"issue":"4","key":"1699_CR7","first-page":"349","volume":"21","author":"DM Wieland","year":"1980","unstructured":"Wieland DM, Wu J, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH. Radiolabeled adrenergi neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med. 1980;21(4):349\u201353.","journal-title":"J Nucl Med"},{"key":"1699_CR8","first-page":"61","volume":"2","author":"B Shapiro","year":"1991","unstructured":"Shapiro B. A review of the status of radio-iodinated-MIBG therapy for neuroendocrine tumors. Int Med. 1991;2:61\u20138.","journal-title":"Int Med"},{"issue":"1","key":"1699_CR9","first-page":"77","volume":"44","author":"MR Castellani","year":"2000","unstructured":"Castellani MR, Chiti A, Seregni E, Bombardieri E. Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours Experience of the National Cancer Institute of Milan. Q J Nucl Med Off Publ Ital Assoc Nucl Med. 2000;44(1):77\u201387.","journal-title":"Q J Nucl Med Off Publ Ital Assoc Nucl Med"},{"issue":"6","key":"1699_CR10","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0039-6060(03)00426-4","volume":"134","author":"SD Safford","year":"2003","unstructured":"Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman JM, Leight GS Jr, et al. Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery. 2003;134(6):956\u201362 (discussion 62-3).","journal-title":"Surgery"},{"issue":"4","key":"1699_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/cen.12341","volume":"80","author":"LT van Hulsteijn","year":"2014","unstructured":"van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EP. (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. Clin Endocrinol. 2014;80(4):487\u2013501.","journal-title":"Clin Endocrinol"},{"issue":"1","key":"1699_CR12","doi-asserted-by":"publisher","first-page":"7625","DOI":"10.1038\/s41598-019-43880-6","volume":"9","author":"H Wakabayashi","year":"2019","unstructured":"Wakabayashi H, Inaki A, Yoshimura K, Murayama T, Imai Y, Higuchi T, et al. A phase I clinical trial for [(131)I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma. Sci Rep. 2019;9(1):7625.","journal-title":"Sci Rep"},{"issue":"34","key":"1699_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2152\/jmi.64.205","volume":"64","author":"A Inaki","year":"2017","unstructured":"Inaki A, Yoshimura K, Murayama T, Imai Y, Kuribayashi Y, Higuchi T, et al. A phase I clinical trial for [(131)I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma: a study protocol. J Med Invest. 2017;64(34):205\u20139.","journal-title":"J Med Invest"},{"issue":"5","key":"1699_CR14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365\u201376.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1699_CR15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","volume":"37","author":"R Brooks","year":"1996","unstructured":"Brooks R. EuroQol: the current state of play. Health Policy. 1996;37(1):53\u201372.","journal-title":"Health Policy"},{"key":"1699_CR16","unstructured":"JAPIC Clinical Trials Information. https:\/\/www.clinicaltrials.jp\/cti-user\/trial\/ShowDirect.jsp?clinicalTrialId=27842."},{"issue":"1","key":"1699_CR17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207\u201314.","journal-title":"Cancer"},{"issue":"4","key":"1699_CR18","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00259-007-0652-6","volume":"35","author":"GK Gedik","year":"2008","unstructured":"Gedik GK, Hoefnagel CA, Bais E, Olmos RA. 131I-MIBG therapy in metastatic pheochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2008;35(4):725\u201333.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"1699_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 11). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"key":"1699_CR20","unstructured":"Japan Clinical Oncology Group. Common terminology criteria for adverse events (CTCAE) version 4.0. http:\/\/www.jcog.jp\/doctor\/tool\/ctcaev4.html."},{"issue":"6","key":"1699_CR21","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1530\/EJE-15-0483","volume":"173","author":"A Riester","year":"2015","unstructured":"Riester A, Weismann D, Quinkler M, Lichtenauer UD, Sommerey S, Halbritter R, et al. Life-threatening events in patients with pheochromocytoma. Eur J Endocrinol. 2015;173(6):757\u201364.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"1699_CR22","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1210\/jc.2018-01968","volume":"104","author":"S Hescot","year":"2019","unstructured":"Hescot S, Curras-Freixes M, Deutschbein T, van Berkel A, Vezzosi D, Amar L, et al. Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono Study): a European network for the study of adrenal tumors retrospective study. J Clin Endocrinol Metab. 2019;104(6):2367\u201374.","journal-title":"J Clin Endocrinol Metab"},{"key":"1699_CR23","doi-asserted-by":"crossref","unstructured":"Yoshinaga K, Oriuchi N, Wakabayashi H, Tomiyama Y, Jinguji M, Higuchi T, et al. Effects and safety of I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry. Endocr J. 2014.","DOI":"10.1507\/endocrj.EJ14-0211"},{"issue":"5","key":"1699_CR24","first-page":"361","volume":"13","author":"A Hartley","year":"2001","unstructured":"Hartley A, Spooner D, Brunt AM. Management of malignant phaeochromocytoma: a retrospective review of the use of MIBG and chemotherapy in the West Midlands. Clin Oncol (R Coll Radiol). 2001;13(5):361\u20136.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1","key":"1699_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1046\/j.1365-2265.2001.01309.x","volume":"55","author":"JJ Mukherjee","year":"2001","unstructured":"Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, et al. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. Clin Endocrinol. 2001;55(1):47\u201360.","journal-title":"Clin Endocrinol"},{"issue":"4","key":"1699_CR26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0936-6555(02)00273-X","volume":"15","author":"JB Bomanji","year":"2003","unstructured":"Bomanji JB, Wong W, Gaze MN, Cassoni A, Waddington W, Solano J, et al. Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy. Clin Oncol (R Coll Radiol). 2003;15(4):193\u20138.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"25","key":"1699_CR27","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","volume":"27","author":"S Gonias","year":"2009","unstructured":"Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol. 2009;27(25):4162\u20138.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1699_CR28","first-page":"100","volume":"54","author":"MR Castellani","year":"2010","unstructured":"Castellani MR, Seghezzi S, Chiesa C, Aliberti GL, Maccauro M, Seregni E, et al. (131)I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy. Q J Nucl Med Mol Imaging Off Publ Ital Assoc Nucl Med. 2010;54(1):100\u201313.","journal-title":"Q J Nucl Med Mol Imaging Off Publ Ital Assoc Nucl Med"},{"issue":"1","key":"1699_CR29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/COC.0b013e31819e2c28","volume":"33","author":"M Shilkrut","year":"2010","unstructured":"Shilkrut M, Bar-Deroma R, Bar-Sela G, Berniger A, Kuten A. Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: single center experience. Am J Clin Oncol. 2010;33(1):79\u201382.","journal-title":"Am J Clin Oncol"},{"issue":"12","key":"1699_CR30","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1097\/MNM.0b013e32834bad97","volume":"32","author":"SH Rachh","year":"2011","unstructured":"Rachh SH, Abhyankar S, Basu S. [(1)(3)(1)I]Metaiodobenzylguanidine therapy in neural crest tumors: varying outcome in different histopathologies. Nucl Med Commun. 2011;32(12):1201\u201310.","journal-title":"Nucl Med Commun"},{"issue":"2","key":"1699_CR31","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s12020-010-9422-5","volume":"39","author":"A Szalat","year":"2011","unstructured":"Szalat A, Fraenkel M, Doviner V, Salmon A, Gross DJ. Malignant pheochromocytoma: predictive factors of malignancy and clinical course in 16 patients at a single tertiary medical center. Endocrine. 2011;39(2):160\u20136.","journal-title":"Endocrine"},{"key":"1699_CR32","doi-asserted-by":"crossref","unstructured":"Fishbein L, Bonner L, Torigian DA, Nathanson KL, Cohen DL, Pryma D, et al. External beam radiation therapy (EBRT) for patients with malignant pheochromocytoma and non-head and -neck paraganglioma: combination with 131I-MIBG. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2012;44(5):405\u201310.","DOI":"10.1055\/s-0032-1308992"},{"issue":"5","key":"1699_CR33","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/cen.12542","volume":"81","author":"ND Niemeijer","year":"2014","unstructured":"Niemeijer ND, Alblas G, van Hulsteijn LT, Dekkers OM, Corssmit EP. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin Endocrinol. 2014;81(5):642\u201351.","journal-title":"Clin Endocrinol"},{"issue":"2","key":"1699_CR34","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s12672-017-0284-7","volume":"8","author":"S Asai","year":"2017","unstructured":"Asai S, Katabami T, Tsuiki M, Tanaka Y, Naruse M. Controlling tumor progression with cyclophosphamide, vincristine, and dacarbazine treatment improves survival in patients with metastatic and unresectable malignant pheochromocytomas\/paragangliomas. Hormones & cancer. 2017;8(2):108\u201318.","journal-title":"Hormones & cancer"},{"key":"1699_CR35","unstructured":"Radiation Emergency Medical Management, U.S. Department of health and human services. Guidelines for Use of Antiemetics. https:\/\/www.remm.nlm.gov\/antiemetics.htm."},{"issue":"3","key":"1699_CR36","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00520-018-4586-2","volume":"27","author":"E McKenzie","year":"2019","unstructured":"McKenzie E, Zaki P, Raman S, Olson R, McFarlane T, DeAngelis C, et al. Radiation-induced nausea and vomiting: a comparison between MASCC\/ESMO, ASCO, and NCCN antiemetic guidelines. Support Care Cancer. 2019;27(3):783\u201391.","journal-title":"Support Care Cancer"},{"issue":"1","key":"1699_CR37","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00520-016-3407-8","volume":"25","author":"CH Ruhlmann","year":"2017","unstructured":"Ruhlmann CH, Jahn F, Jordan K, Dennis K, Maranzano E, Molassiotis A, et al. 2016 updated MASCC\/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting. Support Care Cancer. 2017;25(1):309\u201316.","journal-title":"Support Care Cancer"},{"key":"1699_CR38","doi-asserted-by":"crossref","unstructured":"Feyer P, Jahn F, Jordan K. Prophylactic Management of Radiation-Induced Nausea and Vomiting. Biomed Res Int. 2015;2015:893013.","DOI":"10.1155\/2015\/893013"},{"issue":"3","key":"1699_CR39","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1530\/EJE-15-0456","volume":"173","author":"S Thosani","year":"2015","unstructured":"Thosani S, Ayala-Ramirez M, Roman-Gonzalez A, Zhou S, Thosani N, Bisanz A, et al. Constipation: an overlooked, unmanaged symptom of patients with pheochromocytoma and sympathetic paraganglioma. Eur J Endocrinol. 2015;173(3):377\u201387.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1699_CR40","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00259-008-0715-3","volume":"35","author":"F Giammarile","year":"2008","unstructured":"Giammarile F, Chiti A, Lassmann M, Brans B, Flux G. EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging. 2008;35(5):1039\u201347.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1699_CR41","doi-asserted-by":"crossref","unstructured":"Kinuya S, Yoshinaga K, Higuchi T, Jinguji M, Kurihara H, Kawamoto H. Draft guidelines regarding appropriate use of I-MIBG radiotherapy for neuroendocrine tumors: guideline drafting committee for radiotherapy with I-MIBG, Committee for Nuclear Oncology and Immunology, The Japanese Society of Nuclear Medicine. Ann Nucl Med. 2015.","DOI":"10.1007\/s12149-015-0960-z"},{"issue":"12","key":"1699_CR42","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1038\/s41379-018-0110-y","volume":"31","author":"G Rindi","year":"2018","unstructured":"Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31(12):1770\u201386.","journal-title":"Mod Pathol"},{"issue":"7","key":"1699_CR43","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3390\/cancers11070909","volume":"11","author":"AR Vyakaranam","year":"2019","unstructured":"Vyakaranam AR, Crona J, Norl\u00e9n O, Granberg D, Garske-Rom\u00e1n U, Sandstr\u00f6m M, et al. Favorable outcome in patients with pheochromocytoma and paraganglioma treated with 177Lu-DOTATATE. Cancers. 2019;11(7):909.","journal-title":"Cancers"},{"issue":"9","key":"1699_CR44","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1530\/EC-20-0292","volume":"9","author":"SK Jaiswal","year":"2020","unstructured":"Jaiswal SK, Sarathi V, Memon SS, Garg R, Malhotra G, Verma P, et al. 177Lu-DOTATATE therapy in metastatic\/inoperable pheochromocytoma-paraganglioma. Endocr Connect. 2020;9(9):864\u201373.","journal-title":"Endocr Connect"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-021-01699-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-021-01699-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-021-01699-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T17:03:04Z","timestamp":1646413384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-021-01699-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,6]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1699"],"URL":"https:\/\/doi.org\/10.1007\/s12149-021-01699-0","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,6]]},"assertion":[{"value":"20 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A. Inaki is a member of the working group for preparation of the proper use manual of <sup>131<\/sup>I-mIBG, managed by FUJIFILM Toyama Chemical Co., Ltd., and has performed collaborative research with FUJIFILM Toyama Chemical Co., Ltd., developing <sup>131<\/sup>I-mIBG therapy for patients with high-risk neuroblastoma. S. Watanabe belongs to a department that is partly funded by FUJIFILM Toyama Chemical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}